News for Atea Pharmaceuticals, Inc. (AVIR)

**media[548306]**

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. ( AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the disc

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently made a strategic decision to reduce its holdings in Atea Pharmaceuticals Inc (AVIR

META_DESC_INVESTMENT_IDEA

On January 16, 2025, Franklin Berger, a Director at Atea Pharmaceuticals Inc (AVIR), purchased 25,000 shares of the company, according to a SEC Filing. Followin

Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference

Global Phase 3 HCV Program Expected to Initiate in 1Q 2025 Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt

**media[509149]**

Financial advisor Evercore engaged by Atea Pharmaceuticals (AVIR) to explore ways to enhance shareholder value, including potential strategic partnerships.

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. ( AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the disc

On December 10, 2024, Franklin Berger, a Director at Atea Pharmaceuticals Inc (AVIR), sold 359,606 shares of the company. Following this transaction, the inside

Atea Pharmaceuticals, Inc. (AVIR) Wednesday revealed that its Phase 2 study of Bemnifosbuvir and Ruzasvir Regimen for the treatment of Hepatitis C Virus or HCV achieved primary endpoint of safety and sustained virologic response.

GuruFocus Article or News written by insider and the topic is about:

The biotech sector is down 45% from its March 2021 highs. Read how, if investors doing their homework could uncover opportunities.

/PRNewswire/ -- The newly published report titled "Global COVID-19 Therapeutics Market– By Trends, Industry Competition Analysis, Clinical Trial/Pipeline...

On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new ...

GuruFocus Article or News written by insider and the topic is about:

The first pill to treat Covid-19 is on its way and vaccine producers are rolling out booster shots in wealthy countries. For investors, the next stage of the pandemic means a tougher landscape for stockpicking. Nineteen months into the pandemic, a successful rollout of a Covid-19 pill could quicken and broaden the worlds recovery, opening up a plethora of investment opportunities in stock markets.